Bottom line
ECERX vs VPMCX: the short answer
ECERX (Eaton Vance Stock Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds.
But VPMCX is far broader, holding 173 positions to 1 for ECERX, so beyond the top names it adds exposure ECERX doesn't have.
VPMCX is cheaper at 0.35% vs 1.73% — a difference of $138 a year per $10,000 invested.
Over five years, VPMCX returned +14.3% a year vs +12.5% for ECERX.
Updated Nov 19, 2026
ECERX vs VPMCX side by side
| ECERX | VPMCX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Morgan Stanley | Vanguard |
| Category | Large Blend | Large Blend |
| Expense ratio | 1.73% | 0.35% |
| Annual cost per $10k | $173 | $35 |
| 10-yr cost on $10k (prospectus) | $1,963 | $443 |
| Max front load | 0% | 0% |
| 12b-1 fee | 1% | 0% |
| 1-yr return | +11.4% | +29.9% |
| 5-yr return (annualized) | +12.5% | +14.3% |
| 10-yr return (annualized) | +12.8% | +15.2% |
| Best quarter | — | +17.3% |
| Worst quarter | — | −20.2% |
| Net assets (fund) | $102.1M | $96.1B |
| Number of holdings | 1 | 173 |
| Portfolio turnover | 42% | 11% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
ECERX and VPMCX share none of their top holdings.
ECERX top 10
- Stock Portfolio — 100.01%
VPMCX top 10
- Micron Technology Inc — 13.50%
- Intel Corp — 6.80%
- Eli Lilly & Co — 6.76%
- KLA Corp — 3.85%
- Alphabet Inc — 3.52%
- AstraZeneca PLC — 2.35%
- NVIDIA Corp — 2.33%
- Amazon.com Inc — 2.05%
- Tesla Inc — 1.89%
- Biogen Inc — 1.88%
FAQ
What is the difference between ECERX and VPMCX?
ECERX (Eaton Vance Stock Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds. But VPMCX is far broader, holding 173 positions to 1 for ECERX, so beyond the top names it adds exposure ECERX doesn't have.
Which is cheaper, ECERX or VPMCX?
VPMCX has the lower expense ratio (0.35%).
Should I own both ECERX and VPMCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.